Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07349134 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

WELL-MPN: A Digital Lifestyle App for Patients With MPNs

Study acronym: WELL-MPN
StatusNot Yet Recruiting
PhaseNot applicable
Started2027-01
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later Jan 2029 → Jul 2029
See other at-risk trials from Brigham and Women's Hospital

Amendment history

2026-09-30
notable
Primary completion pushed: 2029-01 → 2029-07
2026-01-16
minor
Study Status, Outcome Measures v1
Secondary endpointsdetails revised at 1 of 7 entries
2026-01-09
minor
Original filing
The goal of this clinical trial is to learn whether a digital lifestyle app can help improve diet, physical activity, symptoms, emotional well-being, and quality of life in adults with myeloproliferative neoplasms (MPNs). The main questions it aims to answer are: Can people with MPNs use the WELL-MPN app? Does using the WELL-MPN app improve diet quality and physical activity? Does the WELL-MPN app improve MPN-related symptoms, anxiety and depression, confidence in managing health, and overall quality of life? Researchers will compare participants who use the WELL-MPN digital app with participants who receive written educational materials about diet and physical activity for people with cancer to see if the app leads to greater improvements in lifestyle behaviors, symptoms, and well-being. Participants will: Be randomly assigned to use the WELL-MPN app or receive written lifestyle education materials Use the assigned program or materials over the study period Complete surveys about diet, physical activity, symptoms, mood, confidence in self-care, and quality of life
Trial Details
NCT Number NCT07349134
Lead Sponsor Brigham and Women's Hospital
Conditions Myeloproliferative Neoplasms (MPNs)
Enrollment 75 participants
Start Date 2027-01
Primary Completion 2029-07 (estimated)
Study Completion 2029-07 (estimated)
Updated on ClinicalTrials.gov 2026-09-29